To assess the potential artificial synthetic lethality and overcome PARPi resistance by inhibiting FASN activity in-vivo, we tested the combination synergism between 5HLS and talazoparib on the BRCA1 wild-type TNBC xenograft tumor. The gene discussed is FASN; the disease is neoplasm.